Table of Contents Author Guidelines Submit a Manuscript
Journal of Parasitology Research
Volume 2010, Article ID 716498, 7 pages
http://dx.doi.org/10.1155/2010/716498
Research Article

In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayi

1The Department of Physiology, Michigan State University, East Lansing, MI 48824, USA
2Department of Biochemistry, University of the Philippines, Manila, Philippines
3Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland
4Biotechnology and Bioengineering Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA

Received 15 June 2010; Revised 22 October 2010; Accepted 23 November 2010

Academic Editor: Nirbhay Kumar

Copyright © 2010 David Wenkert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. H. Pearl and C. Prodromou, “Structure and mechanism of the Hsp90 molecular chaperone machinery,” Annual Review of Biochemistry, vol. 75, pp. 271–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Zhao and W. A. Houry, “Hsp90: a chaperone for protein folding and gene regulation,” Biochemistry and Cell Biology, vol. 83, no. 6, pp. 703–710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. DeBoer, P. A. Meulman, R. J. Wnuk, and D. H. Peterson, “Geldanamycin, a new antibiotic,” Journal of Antibiotics, vol. 23, no. 9, pp. 442–447, 1970. View at Google Scholar · View at Scopus
  4. C. E. Stebbins, A. A. Russo, C. Schneider, N. Rosen, F. U. Hartl, and N. P. Pavletich, “Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent,” Cell, vol. 89, no. 2, pp. 239–250, 1997. View at Google Scholar · View at Scopus
  5. J. P. Grenert, W. P. Sullivan, P. Fadden et al., “The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation,” Journal of Biological Chemistry, vol. 272, no. 38, pp. 23843–23850, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Banerji, I. Judson, and P. Workman, “The clinical applications of heat shock protein inhibitors in cancer—present and future,” Current Cancer Drug Targets, vol. 3, no. 5, pp. 385–390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Workman, “Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone,” Cancer Letters, vol. 206, no. 2, pp. 149–157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. L. David, H. E. Smith, D. A. Raynes, E. J. Pulcini, and L. Whitesell, “Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans,” Cell Stress and Chaperones, vol. 8, no. 1, pp. 93–104, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. N. A. Him, V. Gillan, R. D. Emes, K. Maitland, and E. Devaney, “Hsp-90 and the biology of nematodes,” BMC Evolutionary Biology, vol. 9, no. 1, article no. 254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. A. Sausville, J. E. Tomaszewski, and P. Ivy, “Clinical development of 17-allylamino, 17-demethoxygeldanamycin,” Current Cancer Drug Targets, vol. 3, no. 5, pp. 377–383, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. E. I. Heath, M. Gaskins, H. C. Pitot et al., “A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer,” Clinical Prostate Cancer, vol. 4, no. 2, pp. 138–141, 2005. View at Google Scholar · View at Scopus
  12. E. A. Ronnen, G. V. Kondagunta, N. Ishill et al., “A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma,” Investigational New Drugs, vol. 24, no. 6, pp. 543–546, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. K. Ramanathan, M. J. Egorin, J. L. Eiseman et al., “Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers,” Clinical Cancer Research, vol. 13, no. 6, pp. 1769–1774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Bagatell, L. Gore, M. J. Egorin et al., “Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycinin pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study,” Clinical Cancer Research, vol. 13, no. 6, pp. 1783–1788, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. B. J. Weigel, S. M. Blaney, J. M. Reid et al., “A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children's oncology group study,” Clinical Cancer Research, vol. 13, no. 6, pp. 1789–1793, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. J. Murgo, S. Kummar, E. R. Gardner et al., “Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly,” Journal of Clinical Oncology, vol. 25, p. 3566, 2007. View at Google Scholar
  17. R. C. Schnur and M. L. Corman, “Tandem [3,3]-sigmatropic rearrangements in an ansamycin: stereospecific conversion of an (S)-allylic alcohol to an (S)-allylic amine derivative,” Journal of Organic Chemistry, vol. 59, no. 9, pp. 2581–2584, 1994. View at Google Scholar · View at Scopus
  18. Y. Shen, Q. Xie, M. Norberg, E. Sausville, G. Vande Woude, and D. Wenkert, “Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation,” Bioorganic and Medicinal Chemistry, vol. 13, no. 16, pp. 4960–4971, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. L. Rinehart Jr., M. W. McMillan, and T. R. Witty, “Synthesis of phenazine and phenoxazinone derivatives of geldanamycin as potential polymerase inhibitors,” Bioorganic Chemistry, vol. 6, no. 3, pp. 353–369, 1977. View at Google Scholar · View at Scopus
  20. R. C. Schnur, M. L. Corman, R. J. Gallaschun et al., “erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships,” Journal of Medicinal Chemistry, vol. 38, no. 19, pp. 3813–3820, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Chen, D. Zhong, and A. Monteiro, “Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms,” BMC Genomics, vol. 7, article no. 156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Chène, “ATPases as drug targets: learning from their structure,” Nature Reviews Drug Discovery, vol. 1, no. 9, pp. 665–673, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Devaney, K. O'Neill, W. Harnett, L. Whitesell, and J. H. Kinnaird, “Hsp90 is essential in the filarial nematode Brugia pahangi,” International Journal for Parasitology, vol. 35, no. 6, pp. 627–636, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. R. Pavithra, R. Kumar, and U. Tatu, “Systems analysis of chaperone networks in the malarial parasite Plasmodium falciparum,” PLoS Computational Biology, vol. 3, no. 9, pp. 1701–1715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Kumar, A. Musiyenko, and S. Barik, “The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin,” Malaria Journal, vol. 2, no. 1, article 30, 2003. View at Google Scholar · View at Scopus
  26. G. Banumathy, V. Singh, S. R. Pavithra, and U. Tatu, “Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes,” Journal of Biological Chemistry, vol. 278, no. 20, pp. 18336–18345, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Townson, B. Ramirez, F. Fakorede, M. A. Mouries, and S. Nwaka, “Challenges in drug discovery for novel antifilarials,” Expert Opinion on Drug Discovery, vol. 2, no. 1, pp. S63–S73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kron, F. Yousif, and B. Ramirez, “Capacity building in anthelmintic drug discovery,” Expert Opinion on Drug Discovery, vol. 2, no. 1, pp. S75–S82, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. K. M. Wasan, D. R. Brocks, S. D. Lee, K. Sachs-Barrable, and S. J. Thornton, “Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery,” Nature Reviews Drug Discovery, vol. 7, no. 1, pp. 84–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Ramirez, Q. Bickle, F. Yousif, F. Fakorede, M. A. Mouries, and S. Nwaka, “Schistosomes: challenges in compound screening,” Expert Opinion on Drug Discovery, vol. 2, no. 1, pp. S53–S61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Saenger, G. Laemmler, and P. Kimmig, “Filarial infections of Mastomys natalensis and their relevance for experimental chemotherapy,” Acta Tropica, vol. 38, no. 3, pp. 277–288, 1981. View at Google Scholar
  32. K. E. Kinnamon, R. R. Engle, B. T. Poon, W. Y. Ellis, J. W. McCall, and M. T. Dzimianski, “Anticancer agents suppressive for adult parasites of filariasis in mongolian jirds,” Experimental Biology and Medicine, vol. 224, no. 1, pp. 45–49, 2000. View at Google Scholar · View at Scopus
  33. L. Pica-Mattoccia, M. J. Doenhoff, C. Valle et al., “Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni,” Acta Tropica, vol. 111, no. 1, pp. 82–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Taldone, V. Gillan, W. Sun et al., “Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90,” PLoS Neglected Tropical Diseases, vol. 4, no. 6, article e714, 2010. View at Publisher · View at Google Scholar
  35. J. R. Sydor, E. Normant, C. S. Pien et al., “Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17408–17413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Sõti, E. Nagy, Z. Giricz, L. Vígh, P. Csermely, and P. Ferdinandy, “Heat shock proteins as emerging therapeutic targets,” British Journal of Pharmacology, vol. 146, no. 6, pp. 769–780, 2005. View at Publisher · View at Google Scholar · View at Scopus